ARS Pharmaceuticals, Inc. Operating Lease Cost
ARS Pharmaceuticals, Inc. (SPRY) reported Operating Lease Cost of $334.00 thousand for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-02.
Discontinued › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2022-11-02
- ARS Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2022-09-30 was $334.00K, a 16.92% decline year-over-year.
- ARS Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2022-06-30 was $362.00K, a 4.32% increase year-over-year.
- ARS Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2022-03-31 was $356.00K, a 2.59% increase year-over-year.
- ARS Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2021-12-31 was $356.00K, a 2.59% increase year-over-year.
- ARS Pharmaceuticals, Inc. operating lease, cost for fiscal 2021 was $1.45M, a 4.61% increase from fiscal 2020.
- ARS Pharmaceuticals, Inc. operating lease, cost for fiscal 2020 was $1.39M.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2022-09-30 | $334.00K 10-Q · filed 2022-11-02 | $696.00K derived: sum of 2 quarters · filed 2022-11-02 | $1.05M 10-Q · filed 2022-11-02 | $1.41M derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-06-30 | $362.00K 10-Q · filed 2022-08-11 | $718.00K 10-Q · filed 2022-08-11 | $1.07M derived: sum of 3 quarters · filed 2022-08-11 | $1.48M derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-03-31 | $356.00K 10-Q · filed 2022-05-12 | $712.00K derived: sum of 2 quarters · filed 2022-05-12 | $1.11M derived: sum of 3 quarters · filed 2022-11-02 | $1.46M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-12-31 | $356.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $758.00K derived: sum of 2 quarters · filed 2022-11-02 | $1.10M derived: sum of 3 quarters · filed 2022-11-02 | $1.45M 10-K · filed 2022-03-31 |
| 2021-09-30 | $402.00K 10-Q · filed 2022-11-02 | $749.00K derived: sum of 2 quarters · filed 2022-11-02 | $1.10M 10-Q · filed 2022-11-02 | $1.44M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $347.00K 10-Q · filed 2022-08-11 | $694.00K 10-Q · filed 2022-08-11 | $1.04M derived: sum of 3 quarters · filed 2022-08-11 | $1.39M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $347.00K 10-Q · filed 2022-05-12 | $694.00K derived: sum of 2 quarters · filed 2022-05-12 | $1.04M derived: sum of 3 quarters · filed 2022-05-12 | $1.39M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $347.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $694.00K derived: sum of 2 quarters · filed 2022-03-31 | $1.04M derived: sum of 3 quarters · filed 2022-03-31 | $1.39M 10-K · filed 2022-03-31 |
| 2020-09-30 | $347.00K 10-Q · filed 2021-11-10 | $694.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.04M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $347.00K 10-Q · filed 2021-08-12 | $694.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $347.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |